BRAF V600E in colorectal cancer: what it implies and which treatments exist

What does the BRAF V600E mutation mean in colon cancer?

Reviewed by: Equipo CRC Warriors (pendiente de revisión clínica) Last reviewed: 01/11/2026 Updated: 01/11/2026 2 min
In short: BRAF V600E is found in 8-10 % of colorectal cancers and is linked to more aggressive tumours. The good news is that since 2020 there is a specific targeted treatment (encorafenib with cetuximab) and that, if the tumour is also MSI-H, immunotherapy works very well.

What BRAF V600E is

BRAF is a gene in the same "chain of command" as KRAS. The V600E mutation is by far the most frequent in colon cancer (over 90 % of BRAF mutations) and the one with clear treatment implications. It is found in 8-10 % of colorectal cancers, more often in women, in older people and in right-sided tumours.

Around a third of BRAF V600E tumours are also MSI-H/dMMR; that fact is decisive, because it opens the door to immunotherapy.

What it implies

It should be said plainly: metastatic tumours with BRAF V600E have historically had a worse prognosis and respond less well to conventional chemotherapy. That is why guidelines treat them differently from the start, and why it is so important that the mutation is detected early.

Treatments

If the tumour is MSI-H/dMMR

Immunotherapy (pembrolizumab in first line; nivolumab with or without ipilimumab) is the preferred option, with long-lasting responses in a substantial share of patients.

If the tumour is MSS (stable)

  • First line: traditionally intensive chemotherapy (FOLFOXIRI or FOLFOX) with bevacizumab. Since 2024-2025, the combination of encorafenib + cetuximab + FOLFOX (BREAKWATER study) has shown better first-line results and is being added to guidelines; ask whether it is available at your hospital.
  • After progressing on a first line: encorafenib + cetuximab (BEACON study), approved in Europe since 2020. It is a targeted treatment, oral plus intravenous, with side effects different from chemotherapy (mainly skin, tiredness, nausea, joint pain).

In BRAF V600E, anti-EGFR drugs alone do not work; they only make sense combined with the BRAF inhibitor.

BRAF mutations that are not V600E

The so-called "non-V600" mutations (class 2 and 3) are rare, behave differently and, in general, are not treated with encorafenib. If your report shows a BRAF mutation other than V600E, ask about it specifically.

What to ask at your appointment

  • Is my mutation V600E or another type?
  • Is my tumour MSI-H or MSS? (This completely changes the first option.)
  • Can I receive encorafenib + cetuximab, in first line or the next one?
  • Are there clinical trials for BRAF V600E in my region?
  • Has my case been discussed at the tumour board?

Frequently asked questions

Is BRAF V600E hereditary?

No. It is a mutation acquired by the tumour. If anything, its presence in an MSI-H tumour makes Lynch syndrome less likely, because it usually points to a sporadic origin (MLH1 methylation).

Is encorafenib chemotherapy?

No. It is a targeted therapy in tablet form that blocks the mutated BRAF protein. It is given together with cetuximab (an intravenous antibody every 1-2 weeks). It does not cause hair loss or the typical drop in white cells seen with chemotherapy, but it has its own effects: skin, tiredness, nausea, joint pain.

What is the survival for BRAF V600E colon cancer?

Published medians in metastatic disease were shorter than in other subtypes before targeted treatments. With encorafenib + cetuximab and, in MSI-H, with immunotherapy, results have improved. Averages do not predict an individual case; ask your oncologist to place you according to your MSI status, general health and disease burden.

Are there clinical trials for your case?

Enter your stage, mutations and province and we tell you which trials you meet and why. No account needed, two minutes.

Find trials for my profile

We will let you know when there is news

No account needed: just your email. One weekly email, only when there is something new. Unsubscribe in one click.

We will only use your email for these alerts. CRC Warriors Association, non-profit. Privacy

Sources

This guide is general information prepared by the CRC Warriors Association (non-profit) from public medical sources. It does not replace the assessment of your oncologist or medical team, who know your case. If you spot an error, write to contacto@crcwarriors.org.